SKF 81297 hydrobromide
Dopamine D1-like receptor agonist. Centrally active following systemic administration in vivo.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 370.67. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.7 mL||13.49 mL||26.98 mL|
|5 mM||0.54 mL||2.7 mL||5.4 mL|
|10 mM||0.27 mL||1.35 mL||2.7 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Arnt et al (1988) Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol.Toxicol. 62 121 PMID: 3259694
Peacock et al (1990) The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur.J.Pharmacol. 186 49 PMID: 1980891
Reavill et al (1993) Pharmacological characterization of the discriminative stimulus properties of the dopamine D1 agonist, SKF 81297. Behav.Pharmacol. 4 135 PMID: 11224180
If you know of a relevant reference for SKF 81297 hydrobromide, please let us know.
View Related Products by Product Action
Keywords: D1 agonists Dopamine Receptors D5 dopaminergic SKF81297 hydrobromide D1 and D5 Receptors
8 Citations for SKF 81297 hydrobromide
Citations are publications that use Tocris products. Selected citations for SKF 81297 hydrobromide include:
Urizar et al (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat Neurosci 7 624 PMID: 21785426
Deng et al (2010) MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. PLoS One 13 1128 PMID: 20711186
Meunier et al (2015) Effect of dopaminergic D1 receptors on plasticity is dependent of serotoninergic 5-HT1A receptors in L5-pyramidal neurons of the prefrontal cortex. PLoS One 10 e0120286 PMID: 25775449
Pezze et al (2015) Dopaminergic modulation of appetitive trace conditioning: the role of D1 receptors in medial prefrontal cortex. Mol Med Rep 232 2669 PMID: 25820982
Parnaudeau et al (2014) Glucocorticoid receptor gene inactivation in dopamine-innervated areas selectively decreases behavioral responses to amphetamine. Front Behav Neurosci 8 35 PMID: 24574986
Marley et al (2013) GPR88 reveals a discrete function of primary cilia as selective insulators of GPCR cross-talk. Psychopharmacology (Berl) 8 e70857 PMID: 23936473
Olianas et al (2012) Coincidence signaling of dopamine D1-like and M1 muscarinic receptors in the regulation of cyclic AMP formation and CREB phosphorylation in mouse prefrontal cortex. Neurosignals 21 61 PMID: 22456324
Guha et al (2012) Stimulation of the D5 dopamine receptor acidifies the lysosomal pH of retinal pigmented epithelial cells and decreases accumulation of autofluorescent photoreceptor debris. J Neurochem 122 823 PMID: 22639870
Do you know of a great paper that uses SKF 81297 hydrobromide from Tocris? If so please let us know.
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.